R21 phase: 2/1/2016 – 1/31/2017
R33 phase: 2/1/2017 – 7/31/2020
Red blood cell microparticles (RMPs) to reduce bleeding following hemorrhagic stroke.
NIH/NINDS (R33 phase will depend on results of R21 phase)
R21NS094896 (IGNITE mechanism) Dr. Dave (PI)
The major goal of this project is to lower hematoma growth following intracerebral hemorrhage using RMPs.
08/01/2019-07/30/2022
Florida Department of Heath Dr. Dave, (Principal Investigator)
Nicotine exposure and intracerebral hemorrhage.
These proposed studies will test efficacy of red blood cell microparticles (RMP) to limit hematoma expansion in a clinically relevant animal model of spontaneous intracerebral hemorrhage.
R33 phase: 2/1/2017 – 7/31/2020
Red blood cell microparticles (RMPs) to reduce bleeding following hemorrhagic stroke.
NIH/NINDS (R33 phase will depend on results of R21 phase)
R21NS094896 (IGNITE mechanism) Dr. Dave (PI)
The major goal of this project is to lower hematoma growth following intracerebral hemorrhage using RMPs.
08/01/2019-07/30/2022
Florida Department of Heath Dr. Dave, (Principal Investigator)
Nicotine exposure and intracerebral hemorrhage.
These proposed studies will test efficacy of red blood cell microparticles (RMP) to limit hematoma expansion in a clinically relevant animal model of spontaneous intracerebral hemorrhage.
Proudly powered by Weebly